RIYADH — Alfaisal University has partnered with Japan’s Medident in a memorandum of understanding (MoU) aimed at creating a new model for equitable, technology-driven healthcare innovation. The collaboration, which aligns with Saudi Arabia’s Vision 2030, was formalized at a signing ceremony at the Saudi Arabia Pavilion at the Osaka-Kansai Expo.
The agreement brings together Alfaisal’s institutional vision with Japan’s expertise in precision medicine, technology integration, and multidisciplinary care.
Initial projects under the agreement, set to begin in late 2025 at Alfaisal’s Health Innovation Center in Riyadh, will include AI-driven diagnostic trials, immersive medical education, and faculty exchanges. The partnership will also focus on developing innovation labs for AI diagnostics, XR surgical training, and 3D-printed biomaterials, and on the digitalization of the healthcare system.
Other key benefits of the partnership will be co-developed certification programs, cross-border support for health-tech startups, and collaborative research into emerging health technologies.
Noor Al-Saadoun, Director of Health Innovation at Alfaisal University’s Biotech Center, highlighted the significance of the partnership. “When global innovators like Japan choose Riyadh as their primary partner, they validate what Vision 2030 engineered: a sovereign ecosystem where regulatory agility, integrated infrastructure, and unwavering national commitment converge,” she said.
